« Back to Record
Citation APA

Dixon, B. P., Kavanagh, D. D., Aris, A. D. M., Adams, B., Kang, H. G., Wang, E., Garlo, K., Ogawa, M., Amancha, P., Chakravarty, S., Heyne, N., Kim, S. H., Cataland, S., Yoon, S. S., Miyakawa, Y., Luque, Y., Muff-Luett, M., Tanaka, K., & Greenbaum, L. L. (2024). Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials. Kidney Medicine, 6(8), 100855. doi:10.1016/j.xkme.2024.100855


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/376801

Dixon, B. P., Kavanagh, D. D., Aris, A. D. M., Adams, B., Kang, H. G., Wang, E., Garlo, K., Ogawa, M., Amancha, P., Chakravarty, S., Heyne, N., Kim, S. H., Cataland, S., Yoon, S. S., Miyakawa, Y., Luque, Y., Muff-Luett, M., Tanaka, K., & Greenbaum, L. L. (2024). Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials. Kidney Medicine, 6(8), 100855. doi:10.1016/j.xkme.2024.100855